Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?

Annals of Pharmacotherapy

Volumn 51, Issue 9, 2017, Pages 804-810

  Chapin, Ryan W ^a   Lee, Tiffany ^a   McCoy, Christopher ^a   Alonso, Carolyn D ^a   Mahoney, Monica V ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

bezlotoxumab; Clostridium difficile; monoclonal antibody

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BACTERIAL TOXIN; BEZLOTOXUMAB; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM INFECTION; DRUG EFFECTS; HUMAN; METABOLISM; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; RECURRENT DISEASE; SECONDARY PREVENTION; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLINICAL TRIALS AS TOPIC; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; RECURRENCE; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 85027417712     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028017706374     Document Type: Review

References (28)

1. Cohen SH, Gerding DN, Johnson S. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431-455. doi:10.0086/651706
2. Shields K, Araujo-Castillo RV, Theethira TG, Alonso CD, Kelly CP., Recurrent Clostridium difficile infection: from colonization to cure. Anaerobe. 2015;34:59-73. doi:10.1016/j.anaerobe.2015.04.012
3. Leav BA, Blair B, Leney M. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine. 2010;28:965-969. doi:10.1016/j.vaccine.2009.10.144
4. Wilcox MH, Gerding DN, Poxton IR. Bezlotoxumab for prevention of Clostridium difficile infection. N Engl J Med. 2017;376:305-317. doi:10.1056/NEJMoa1602615
5. Gupta SB, Mehta V, Dubberke ER. Antibodies to toxin B are protective against Clostridium difficile infection recurrence. Clin Infect Dis. 2016;63:730-734. doi:10.1093/cid/ciw364
6. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. http://www.cdc.gov/drugresistance/threat-report-2013/. Accessed November 30, 2016.
7. Stevens VW, Nelson RE, Schwab-Daugherty EM. Comparative effectiveness of vancomycin and metronidazole for the prevention of recurrence and death in patients with Clostridium difficile infection. JAMA Intern Med. 2017;177(4);546–553.doi:10.1001/jamainternmed.2016.9045
8. Olsen MA, Yan Y, Reske KA, Zilberberg M, Dubberke ER., Impact of Clostridium difficile recurrence on hospital readmissions. Am J Infect Control. 2015;43:318-322. doi:10.1016/j.ajic.2014.12.020
9. Olsen MA, Yan Y, Reske KA, Zilberberg MD, Dubberke ER., Recurrent Clostridium difficile infection is associated with increased mortality. Clin Microbiol Infect. 2015;21:164-170. doi:10.1016/j.cmi.2014.08.017
10. Dificid (fidaxomicin) [prescribing information]. Whitehouse Station, NJ: Merck & Co, Inc; 2015.
11. Zinplava (bezlotoxumab) [prescribing information]. Whitehouse Station, NJ: Merck & Co, Inc; 2016.
12. Orth P, Xiao L, Hernandez LD. Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography. J Biol Chem. 2014 289:18008-18021. doi:10.1074/jbc.M114.560748
13. Lowy I, Molrine DC, Leav BA. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362:197-205. doi:10.1056/NEJMoa0907635
14. US Food and Drug Administration. FDA briefing document: bezlotoxumab injection. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM505290.pdf. Accessed January 19, 2017.
15. Yang Z, Ramsey J, Hamza T. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun. 2015;83:822-831. doi:10.1128/IAI.02897-14
16. US Food and Drug Administration. BLA 761046: bezlotoxumab injection. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM505291.pdf. Accessed January 19, 2017.
17. Taylor CP, Tummala S, Molrine D. Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine. 2008;26:3404-3409. doi:10.1016/j.vaccine.2008.04.042
18. Zar FA, Bakkanagari SR, Moorthi KMLST, Davis MB., A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302-307.
19. Bezlotoxumab for prevention of Clostridium difficile infection recurrence: supplementary appendix. http://www.nejm.org/doi/suppl/10.1056/NEJMoa1602615/suppl_file/nejmoa1602615_appendix.pdf. Accessed January 26, 2017.
20. US Food and Drug Administration. FDA antimicrobial drugs advisory committee meeting. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm507577.pdf. Accessed January 26, 2017.
21. Drug information Lexicomp: (bezlotoxumab). https://www.uptodate.com/contents/bezlotoxumab-drug-information?source=search_result&search=bezlotoxumab&selectedTitle=1~7. Accessed on March 17, 2017.
22. Visweth V, Hincapie AL, Yu M, Khatchatourian L, Nowak MA., Development of a bedside scoring system for predicting a first recurrence of Clostridium difficile-associated diarrhea. Am J Health Syst Pharm. 2017;74:474-482. doi:10.2146/ajhp160186
23. Zilberberg MD, Reske K, Olsen M, Yan Y, Dubberke ER., Development and validation of a recurrent Clostridium difficile risk-prediction model. J Hosp Med. 2014;9:418-423. doi:10.1002/jhm.2189
24. Louie TJ, Miller MA, Mullane KM. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422-431. doi:10.1056/NEJMoa0910812
25. Cornely OA, Crook DW, Esposito R. Fidaoxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomized controlled trial. Lancet Infect Dis. 2012;12:281-289. doi:10.1016/S1473-3099(11)70374-7
26. van Nood E, Vrieze A, Nieuwdorp M. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407-415. doi:10.1056/NEJMoa1205037
27. Hota SS, Sales V, Tomlinson G. Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent Clostridium difficile infection: an open-label, randomized controlled trial. Clin Infect Dis. 2017;64:265-271. doi:10.1093/cid/ciw731
28. Carignan A, Poulin S, Martin P. Efficacy of secondary prophylaxis with vancomycin for preventing recurrent Clostridium difficile infections. Am J Gastroenterol. 2016;111:1834-1840. doi:10.1038/ajg.2016.417